cis-4-hydroxy-L-prolinol | 343633-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: cis-4-hydroxy-L-prolinol
• 英文别名: (3R,5R)-5-(hydroxymethyl)pyrrolidin-3-ol
• CAS: 343633-22-7
• 化学式: C₅H₁₁NO₂
• 分子量: 117.148
• InChiKey: CALDMMCNNFPJSI-RFZPGFLSSA-N

物化性质

• 沸点：
  266.1±20.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cis-4-hydroxy-L-prolinol 在 N-甲基吗啉 、 咪唑 、 氨 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.08h， 生成 1-{2-[(2R,4S)-2-(tert-Butyl-dimethyl-silanyloxymethyl)-4-hydroxy-pyrrolidin-1-yl]-2-oxo-ethyl}-5-methyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Oligonucleotide Analogues with 4-Hydroxy-N-Acetylprolinol as Sugar Substitute

  摘要：

  AbstractModified oligonucleotides incorporating trans‐4‐hydroxy‐N‐acetyl‐L‐prolinol (trans‐4‐HO‐L‐NAP) or its D‐analogue as sugar substitute were synthesised with adenine and thymine as nucleobases. All‐adenine oligonucleotides built from (2S,4S) or (2R,4R)‐cis‐4‐hydroxy‐N‐acetylprolinol were likewise prepared. Hybridisation studies revealed that heterocomplexes formed between polyU and homochiral trans‐4‐hydroxy‐N‐acetylprolinol‐based oligomers of the same as well as of opposite chirality (polyU/trans‐DA*13 and polyU/trans‐LA*13). The former, however, were triple‐stranded. Other complexes with ribonucleic acids were polyA/trans‐LT*13 and polyU/cis‐LA*13. Heteroduplexes with deoxynucleic acids were formed between trans‐LA*13 and oligothymidylate. Interaction was also observed for cis‐LA*13 and oligothymidylate, but not with the D‐hydroxyprolinol analogues. Microcalorimetry proved this interaction to be the formation of a triple‐stranded complex. Two heteroduplexes, trans‐LA*13/dT13 and trans‐LA*13/polyU, had similar or slightly increased stability when compared to the natural dA13/dT13 or dA13/polyU systems. Microcalorimetry clearly indicated the formation of a duplex, in contrast to interactions with N‐acetylprolinol oligonucleotides of different stereochemistry. Moreover, the enthalpy change was of the same magnitude but the association constant was slightly lower. Natural nucleic acids thus clearly prefer hybridisation with L‐hydroxyprolinol oligomers over D‐hydroxyprolinol oligomers. For the series investigated, the L‐trans oligomers (Figure 1) seem best to mimic natural oligonucleotides. These modified oligonucleotides formed homocomplexes if both strands were of the same chirality, that is, homocomplexes formed between trans‐LA* and trans‐LT* and between trans‐DA* and trans‐DT*, reflecting the isochiral pu‐py pairing found in natural nucleic acids. Once more, however, calorimetry proved these to be triplex interactions. Heterochiral pairing was not observed between modified oligonucleotides, but only between modified oligonucleotides and natural polyU. The thermal stabilities of these heterochiral complexes differed clearly.

  DOI：

  10.1002/chem.19970031215
• 作为产物：
  描述：

  N-CBZ-顺式-4-羟基-D-脯氨酸甲酯 在 palladium on activated charcoal 锂硼氢 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 cis-4-hydroxy-L-prolinol
  参考文献：
  名称：

  Ceulemans, G.; Aerschot, A. Van; Herdewijn, P., Collection of Czechoslovak Chemical Communications, 1996, vol. 61, p. S234 - S237

  摘要：

  DOI：

文献信息

• Prolinol-based nucleoside phosphonic acids: new isosteric conformationally flexible nucleotide analogues
  作者：Václav Vaněk、Miloš Buděšínský、Markéta Rinnová、Ivan Rosenberg

  DOI：10.1016/j.tet.2008.11.035

  日期：2009.1

  for the synthesis of prolinol-based nucleotide analogues with an N-phosphonomethyl moiety attached to the prolinol ring nitrogen atom. The synthetic methodology based on the inversion of configuration at both 1- and 4-position led to all diastereoisomeric O-protected 4-mesyloxyprolinol-N-phosphonates. Alkylation of nucleobases using the synthons in the l-series afforded the nucleotide analogues corresponding

  反式-4-羟基-1-脯氨酸已经用作合成基于脯氨醇的核苷酸类似物的起始原料，该核苷酸类似物具有与脯氨醇环氮原子连接的N-膦酰基甲基部分。基于在1-和4-位上的构型反转的合成方法学导致所有非对映异构的O-保护的4-甲磺酰脯氨醇-N-膦酸酯。使用合成子在核碱基的烷基化升-series得到对应于α-核苷酸类似物升-和β-升个核苷酸。在两个不同的pH值下进行的在水溶液中的这些化合物的基于NMR的构象的研究中，示出了任一Ñ-完全质子化或去质子化的形式，揭示了在两种情况下都出现了相同的，大部分为种群的构象体。测试了所有最终的基于1-脯氨醇的核苷膦酸的细胞毒性和抗病毒特性，但未发现明显的活性。
• Isoquinoline compound and pharmaceutical use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US20040248931A1

  公开（公告）日：2004-12-09

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. 1 wherein the symbols are the same as defined in the description.

  本发明涉及一种由以下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和其溶剂合物，以及用于预防和/或治疗由多聚（ADP-核糖）聚合酶的高反应性引起的疾病的药物，其中包含该化合物，以及含有该化合物的多聚（ADP-核糖）聚合酶抑制剂。此外，该化合物可用作预防和/或治疗脑梗死的药物，特别是作为预防和/或治疗急性脑梗死的药物。此外，该化合物可用作预防和/或治疗与脑梗死相关的神经症状的预防和/或治疗剂，特别是急性脑梗死。其中符号与说明中定义的相同。
• ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Fujio Masakazu

  公开号：US20070161620A1

  公开（公告）日：2007-07-12

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.

  本发明涉及以下式(I)所表示的异喹啉化合物，其手性活性形式，其药学上可接受的盐，其水加合物，其水合物和其溶剂化物，以及包含该化合物的用于预防和/或治疗由多聚(ADP-核糖)聚合酶过度反应所致疾病的药剂和包含该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外，该化合物可用作预防和/或治疗脑梗死的药剂，特别是作为预防和/或治疗急性脑梗死的药剂。此外，该化合物可用作改善与脑梗死相关的神经症状的预防性和/或治疗性药剂，特别是急性脑梗死。其中符号与描述中定义的相同。
• WO2008/24725
  申请人：——

  公开号：——

  公开（公告）日：——
• Ceulemans, G.; Aerschot, A. Van; Herdewijn, P., Collection of Czechoslovak Chemical Communications, 1996, vol. 61, p. S234 - S237
  作者：Ceulemans, G.、Aerschot, A. Van、Herdewijn, P.

  DOI：——

  日期：——